Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome.
Steg PG, Szarek M, Valgimigli M, Islam S, Zeiher AM, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Gotcheva N, Harrington RA, Jukema JW, Kim HS, Kim SH, Morais J, Pordy R, Scemama M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Steg PG, et al. Among authors: jukema jw. Can J Cardiol. 2023 Oct;39(10):1315-1324. doi: 10.1016/j.cjca.2023.04.018. Epub 2023 Apr 26. Can J Cardiol. 2023. PMID: 37116789 Free article.
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB; RUBY-1 Investigators. Steg PG, et al. Among authors: jukema jw. Eur Heart J. 2011 Oct;32(20):2541-54. doi: 10.1093/eurheartj/ehr334. Epub 2011 Aug 30. Eur Heart J. 2011. PMID: 21878434 Free PMC article. Clinical Trial.
Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab.
Schwartz GG, Szarek M, Zeiher A, White HD, Jukema JW, Harrington RA, Goodman SG, Diaz R, Bittner V, Bhatt DL, Steg PG. Schwartz GG, et al. Among authors: jukema jw. J Am Coll Cardiol. 2022 Dec 13;80(24):2356-2359. doi: 10.1016/j.jacc.2022.09.035. Epub 2022 Oct 31. J Am Coll Cardiol. 2022. PMID: 36328873 Free article. No abstract available.
Evolving use and clinical outcomes of coronary intravascular lithotripsy: insights from an international, multicentre registry.
van Oort MJH, Al Amri I, Bingen BO, Oliveri F, Claessen BEPM, Dimitriu-Leen AC, Vossenberg TN, Kefer J, Girgis H, van der Kley F, Jukema JW, Montero-Cabezas JM. van Oort MJH, et al. Among authors: jukema jw. Heart. 2024 Oct 29:heartjnl-2024-324703. doi: 10.1136/heartjnl-2024-324703. Online ahead of print. Heart. 2024. PMID: 39472046
Procedural and clinical impact of intracoronary lithotripsy in heavily calcified aorto-ostial coronary lesions.
Oliveri F, Meijer M, Van Oort MJH, Al Amri I, Bingen BO, Claessen BE, Dimitriu-Leen AC, Kefer J, Girgis H, Vossenberg T, Van der Kley F, Jukema JW, Montero-Cabezas JM. Oliveri F, et al. Among authors: jukema jw. Catheter Cardiovasc Interv. 2024 Nov;104(5):881-890. doi: 10.1002/ccd.31233. Epub 2024 Sep 23. Catheter Cardiovasc Interv. 2024. PMID: 39314043
Arterial inflammation on [18F]FDG PET/CT in melanoma patients treated with and without immune checkpoint inhibitors: CHECK-FLAME I.
Polomski EAS, Kapiteijn EW, Heemelaar JC, van der Kolk AV, Kalisvaart TM, van de Burgt A, Dibbets-Schneider P, van Velden FHP, Seijkens TTP, Stöger JL, Jukema JW, de Geus-Oei LF, Antoni ML. Polomski EAS, et al. Among authors: jukema jw. Atherosclerosis. 2024 Sep 7;398:118595. doi: 10.1016/j.atherosclerosis.2024.118595. Online ahead of print. Atherosclerosis. 2024. PMID: 39307054 Free article.
1,125 results